PMC:7212965 / 39146-39809 JSONTXT

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T202","span":{"begin":121,"end":126},"obj":"Disease"},{"id":"T203","span":{"begin":455,"end":463},"obj":"Disease"}],"attributes":[{"id":"A202","pred":"mondo_id","subj":"T202","obj":"http://purl.obolibrary.org/obo/MONDO_0005737"},{"id":"A203","pred":"mondo_id","subj":"T203","obj":"http://purl.obolibrary.org/obo/MONDO_0001673"}],"text":"Limited data regarding GI adverse events are available, as phase 3 trials are still underway. Based on studies regarding Ebola, there have been reports of elevated transaminases, although the severity and incidence have not been quantified.87 There is 1 published case series (n = 53) on compassionate use of remdesivir in COVID-19.88 In this study, the most common adverse effects were notably Gl and hepatotoxicity. Five of 53 patients (9%) experienced diarrhea and 12 of 53 patients (23%) had reported elevations in hepatic enzymes associated with remdesivir. Of 4 patients (8%) who discontinued treatment prematurely, 2 were due to elevated aminotransferases."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T70","span":{"begin":23,"end":25},"obj":"Chemical"},{"id":"T71","span":{"begin":309,"end":319},"obj":"Chemical"},{"id":"T72","span":{"begin":551,"end":561},"obj":"Chemical"}],"attributes":[{"id":"A70","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_73907"},{"id":"A71","pred":"chebi_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"},{"id":"A72","pred":"chebi_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_145994"}],"text":"Limited data regarding GI adverse events are available, as phase 3 trials are still underway. Based on studies regarding Ebola, there have been reports of elevated transaminases, although the severity and incidence have not been quantified.87 There is 1 published case series (n = 53) on compassionate use of remdesivir in COVID-19.88 In this study, the most common adverse effects were notably Gl and hepatotoxicity. Five of 53 patients (9%) experienced diarrhea and 12 of 53 patients (23%) had reported elevations in hepatic enzymes associated with remdesivir. Of 4 patients (8%) who discontinued treatment prematurely, 2 were due to elevated aminotransferases."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T177","span":{"begin":155,"end":177},"obj":"Phenotype"},{"id":"T178","span":{"begin":455,"end":463},"obj":"Phenotype"}],"attributes":[{"id":"A177","pred":"hp_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/HP_0002910"},{"id":"A178","pred":"hp_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/HP_0002014"}],"text":"Limited data regarding GI adverse events are available, as phase 3 trials are still underway. Based on studies regarding Ebola, there have been reports of elevated transaminases, although the severity and incidence have not been quantified.87 There is 1 published case series (n = 53) on compassionate use of remdesivir in COVID-19.88 In this study, the most common adverse effects were notably Gl and hepatotoxicity. Five of 53 patients (9%) experienced diarrhea and 12 of 53 patients (23%) had reported elevations in hepatic enzymes associated with remdesivir. Of 4 patients (8%) who discontinued treatment prematurely, 2 were due to elevated aminotransferases."}

{"project":"2_test","denotations":[{"id":"32407808-31774950-43469308","span":{"begin":240,"end":242},"obj":"31774950"}],"text":"Limited data regarding GI adverse events are available, as phase 3 trials are still underway. Based on studies regarding Ebola, there have been reports of elevated transaminases, although the severity and incidence have not been quantified.87 There is 1 published case series (n = 53) on compassionate use of remdesivir in COVID-19.88 In this study, the most common adverse effects were notably Gl and hepatotoxicity. Five of 53 patients (9%) experienced diarrhea and 12 of 53 patients (23%) had reported elevations in hepatic enzymes associated with remdesivir. Of 4 patients (8%) who discontinued treatment prematurely, 2 were due to elevated aminotransferases."}

{"project":"LitCovid-sentences","denotations":[{"id":"T245","span":{"begin":0,"end":93},"obj":"Sentence"},{"id":"T246","span":{"begin":94,"end":417},"obj":"Sentence"},{"id":"T247","span":{"begin":418,"end":562},"obj":"Sentence"},{"id":"T248","span":{"begin":563,"end":663},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Limited data regarding GI adverse events are available, as phase 3 trials are still underway. Based on studies regarding Ebola, there have been reports of elevated transaminases, although the severity and incidence have not been quantified.87 There is 1 published case series (n = 53) on compassionate use of remdesivir in COVID-19.88 In this study, the most common adverse effects were notably Gl and hepatotoxicity. Five of 53 patients (9%) experienced diarrhea and 12 of 53 patients (23%) had reported elevations in hepatic enzymes associated with remdesivir. Of 4 patients (8%) who discontinued treatment prematurely, 2 were due to elevated aminotransferases."}

{"project":"LitCovid-PubTator","denotations":[{"id":"1022","span":{"begin":23,"end":25},"obj":"Gene"},{"id":"1023","span":{"begin":121,"end":126},"obj":"Species"},{"id":"1024","span":{"begin":429,"end":437},"obj":"Species"},{"id":"1025","span":{"begin":477,"end":485},"obj":"Species"},{"id":"1026","span":{"begin":568,"end":576},"obj":"Species"},{"id":"1027","span":{"begin":309,"end":319},"obj":"Chemical"},{"id":"1028","span":{"begin":551,"end":561},"obj":"Chemical"},{"id":"1029","span":{"begin":323,"end":331},"obj":"Disease"},{"id":"1030","span":{"begin":402,"end":416},"obj":"Disease"},{"id":"1031","span":{"begin":455,"end":463},"obj":"Disease"}],"attributes":[{"id":"A1022","pred":"tao:has_database_id","subj":"1022","obj":"Gene:2770"},{"id":"A1023","pred":"tao:has_database_id","subj":"1023","obj":"Tax:1570291"},{"id":"A1024","pred":"tao:has_database_id","subj":"1024","obj":"Tax:9606"},{"id":"A1025","pred":"tao:has_database_id","subj":"1025","obj":"Tax:9606"},{"id":"A1026","pred":"tao:has_database_id","subj":"1026","obj":"Tax:9606"},{"id":"A1027","pred":"tao:has_database_id","subj":"1027","obj":"MESH:C000606551"},{"id":"A1028","pred":"tao:has_database_id","subj":"1028","obj":"MESH:C000606551"},{"id":"A1029","pred":"tao:has_database_id","subj":"1029","obj":"MESH:C000657245"},{"id":"A1030","pred":"tao:has_database_id","subj":"1030","obj":"MESH:D056486"},{"id":"A1031","pred":"tao:has_database_id","subj":"1031","obj":"MESH:D003967"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Limited data regarding GI adverse events are available, as phase 3 trials are still underway. Based on studies regarding Ebola, there have been reports of elevated transaminases, although the severity and incidence have not been quantified.87 There is 1 published case series (n = 53) on compassionate use of remdesivir in COVID-19.88 In this study, the most common adverse effects were notably Gl and hepatotoxicity. Five of 53 patients (9%) experienced diarrhea and 12 of 53 patients (23%) had reported elevations in hepatic enzymes associated with remdesivir. Of 4 patients (8%) who discontinued treatment prematurely, 2 were due to elevated aminotransferases."}